MetaCap

Inventiva S.A. American Depository Shares (IVA) vs Obsidian Therapeutics (OBX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inventiva S.A. American Depository Shares is the larger company by market cap ($750.8 million vs $741.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IVA-31.74%OBX-31.43%
+107%+27%-52%
Jul 27, 20261 yearNov 20, 2026
IVA-29.91%OBX-23.18%
+82%+21%-40%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IVA versus OBX key metrics
MetricIVAOBX
Share price$3.14$12.00
Market cap$750.78M$741.29M
1-day change-8.99%-1.23%
YTD return-32.47%—
1-year return-26.98%—
5-year return-76.53%—
EPS (TTM)$-0.62$-6.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-49.63M—
52-week high$7.29$49.97
52-week low$2.82$9.60
Distance from 52-week high-56.93%-75.99%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+359.24%+222.25%
Average volume2.40M511.50K
Shares outstanding239.10M61.77M
Employees8787
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Inventiva S.A. American Depository Shares

IVA stock →

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Obsidian Therapeutics

OBX stock →

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

IVA vs OBX FAQ

Which is bigger, Inventiva S.A. American Depository Shares or Obsidian Therapeutics?

Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $750.78M compared with $741.29M for Obsidian Therapeutics (OBX).

Are Inventiva S.A. American Depository Shares and Obsidian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons